Payment overview · 2025
General Payments
$137.47
8 reported records · 6 companies
Healthcare provider profile · identity verified
Tabitha Dawn Culver, MD
Allopathic & Osteopathic Physicians|Family Medicine · LEXINGTON, KY · NPI 1508090424
Verified facts
What the public records show
CMS Open Payments records show Tabitha Dawn Culver, MD received $137.47 in general payments during 2025 across 8 reported records.
ABBVIE INC. accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.81 | 30.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.69 | 21.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.37 | 14.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.27 | 11.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.30 | 11.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $14.03 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $137.47 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.69 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.71 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 490 | 153 |
| Levothyroxine Sodium | Levothyroxine Sodium | 455 | 132 |
| Gabapentin | Gabapentin | 429 | 87 |
| Lisinopril | Lisinopril | 359 | 106 |
| Omeprazole | Omeprazole | 287 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 272 | 85 |
| Losartan Potassium | Losartan Potassium | 255 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 250 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 211 | 72 |
| Metformin Hcl Er | Metformin Hcl | 173 | 54 |
| Carvedilol | Carvedilol | 144 | 41 |
| Tramadol Hcl | Tramadol Hcl | 134 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 40 |
| Montelukast Sodium | Montelukast Sodium | 118 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 117 | 19 |
| Sertraline Hcl | Sertraline Hcl | 113 | 33 |
| Trazodone Hcl | Trazodone Hcl | 107 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 30 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 103 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 30 |
| Famotidine | Famotidine | 95 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 26 |
| Jardiance | Empagliflozin | 90 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 26 |
| Lorazepam | Lorazepam | 83 | 21 |
| Metformin Hcl | Metformin Hcl | 79 | 24 |
| Atenolol | Atenolol | 78 | 20 |
| Eliquis | Apixaban | 77 | 25 |
| Fluconazole | Fluconazole | 77 | 43 |
| Potassium Chloride | Potassium Chloride | 74 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 19 |
| Mounjaro | Tirzepatide | 72 | 11 |
| Spironolactone | Spironolactone | 72 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 21 |
| Simvastatin | Simvastatin | 66 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 21 |
| Allopurinol | Allopurinol | 63 | 20 |
| Furosemide | Furosemide | 63 | 23 |
| Synthroid | Levothyroxine Sodium | 61 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | 14 |
| Estradiol | Estradiol | 56 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 14 |
| Meloxicam | Meloxicam | 52 | 22 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 50 | 15 |
| Promethazine Hcl | Promethazine Hcl | 49 | 16 |
| Buspirone Hcl | Buspirone Hcl | 48 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 13 |
| Celecoxib | Celecoxib | 47 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Chlorthalidone | Chlorthalidone | 46 | 15 |
| Nitroglycerin | Nitroglycerin | 46 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 13 |
| Glipizide | Glipizide | 44 | 13 |
| Irbesartan | Irbesartan | 44 | 16 |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 42 | 12 |
| Prednisone | Prednisone | 42 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 15 |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 11 |
| Farxiga | Dapagliflozin Propanediol | 40 | 11 |
| Meclizine Hcl | Meclizine Hcl | 39 | 12 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 13 |
| Ondansetron Odt | Ondansetron | 38 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 12 |
| Azelastine Hcl | Azelastine Hcl | 37 | 11 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 36 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | 12 |
| Cefuroxime | Cefuroxime Axetil | 30 | 28 |
| Ipratropium Bromide | Ipratropium Bromide | 30 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Baclofen | Baclofen | 27 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Nystatin | Nystatin | 24 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Triazolam | Triazolam | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 12 |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 17 |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 15 |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $137.47 · 8 records | ABBVIE INC. | Dexcom G6 Transmitter, OTEZLA, QULIPTA, REPATHA, SPRAVATO, TRELEGY ELLIPTA, VRAYLAR, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Wegovy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error